Citrulline Efficacy to Improve Carbohydrate Metabolism Abnormalities in the Patient Treated With High Doses of Statin

Inclusion Criteria: * 40 years old \< Age \<75 years old * men and women who are menopausal or who benefit from effective contraception * treatment with atorvastatin at 40 or 80 mg / d for more than 3 months for primary prevention or secondary prevention at more than 3 months of the acute event (stroke, acute coronary syndrome) with or without ezetimibe (Ezetrol® monotherapy or in the form of associated with atorvastatin Liptruzet® 10/40 or 10/80) * with a Body Mass Index (BMI) ≥28 kg / m2 and at least one other risk factor for statin-dependent diabetes among the following 4: * Blood pressure ≥ 140/90 mmHg or hypotensive treatment * Triglyceridemia ≥ 150 mg / l * Fasting blood glucose ≥ 100 mg / dl * HDL-cholesterol \<40 mg / dL in men, \<50 mg / dL in women * affiliated to a social security scheme * signed informed consent Exclusion Criteria: \- General criteria: * Subject with unstable medical or psychological conditions that, in the opinion of the investigator, could lead the subject to be non-compliant or uncooperative during the study or could compromise the safety or participation of the subject under study L.1121-6, L.1121-8, L.1121-9 and L1122-1-2 of the Public Health Code). * Major subjects under guardianship or deprived of their liberty by judicial or administrative decision. * Plan for weight loss during the previous 3 months, current or future * Dietary supplements for weight loss (based on plant extracts, algae, pre- and probiotics) in the previous 3 months or in progress Biological criteria: * Aspartate Amino Transferase (ASAT), Alanine Amino Transferase (ALAT)\> 2 times the normal values * HbA1c\> 6.5% * Creatin Phospho Kinase (CPK)\> 2 times normal * Triglycerid \> 5g / L * Renal insufficiency (clearance \<60 mL / min) * Demonstration of a biological abnormality deemed by the investigator to be clinically significant Medical and therapeutic criteria: * Diabetes type 1 or 2 * Subjects treated with a drug that may interfere with the metabolism of citrulline and glucose (vitamin K antagonists, corticosteroids for more than 8 days before the study, anorexigenic drugs (Anorex, Fenproporex Deglaude AP, Moderatan, Prefamone Chronules), drugs (Orlistat, Lioresal) * Any associated or uncontrolled progressive pathology (cardiac pathology, myocardial infarction of less than 6 months, arterial hypertension, psychiatric, renal or hepatic, cancer). * pregnant or lactating woman * Consumption of more than 3 glasses of alcohol per day. * Subjects who express any reluctance to consume a food supplement morning and evening. * eating disorders. * Weight variation of +/- 5% during the previous 3 months * Severe, progressive affection. * Depressive or psychiatric state (antidepressant or psychotropic treatment). * Medical or surgical history deemed by the investigator to be incompatible with this study. * Blood donation in the 2 months prior to inclusion.